Like other ICI, avelumab can cause immune-related adverse events. Although rare, sarcoidosis-like granulomatous reactions have been described in patients on anti-CTLA-4 and anti-PD-1 immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback